Asia Pacific Nuclear Medicine Market

The Asia Pacific nuclear medicine market is projected to reach USD 4.68 billion by 2030 from USD 2.13 billion in 2025, registering a CAGR of 17.1% during the forecast period. This regional market growth is due to the scale-up of radiopharmaceutical and radioisotope use, which has been facilitated by the development in the volume of procedures. This further increases the production of isotopes domestically and the incorporation of nuclear medicine in the routine clinical practices. Increased investments in cyclotron infrastructure, better access to short half-life isotopes, and exchange demand in its leadership in leading markets, such as China and India, enhance accessibility and reliability of supply. Additionally, the trend toward accurate diagnostics and radioligand-targeted therapies is gaining momentum in adoption, which will lead to robust market growth in the region during the forecast period.

There are two dominant strategic approaches in the Asia Pacific nuclear medicine market. One of them involves localizing and integrating radiopharmaceutical and radioisotope supply chains to overcome the issue of the availability of short half-life isotopes. Several local production units and state-supported organizations, including Sun Pharmaceutical Industries, Inc., are following it, investing in the local cyclotron network and radiopharmaceutical manufacturing. The second strategy revolves around the growth of high-value diagnostic and therapeutic portfolios, especially the PET tracers and theranostic solutions, with the help of imaging technologies and partnerships with hospitals. It is a strategy that is being pursued by players, such as GE HealthCare and Curium, to enhance clinical adoption and remain competitive in Asia Pacific.

To know about the assumptions considered for the study download the pdf brochure

Prominent players operating in the Asia Pacific nuclear medicine market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.P.A (Italy), Pharmalogic Holdings Corp. (US), Sun Pharmaceutical Industries, Inc. (India), Nordion Inc. (Canada), and Siemens Healthineers AG (Germany). These companies are adopting growth strategies, such as acquisitions, agreements, partnerships, and collaborations, to enhance their business.

For instance, in January 2025, Curium Pharma and Telix Pharmaceuticals signed an agreement for Scintimun (99mTc-besilesomab), which is a diagnostic radiopharmaceutical used to image infections. The arrangement assigns the international marketing and distribution rights to Curium and makes Curium a contract manufacturer of the product.

GE HealthCare (US)

GE HealthCare is a significant participant in the Asia Pacific nuclear medicine market, providing a complete range of PET and SPECT radiopharmaceuticals, radioisotope generators, and molecular imaging solutions. The company combines radiopharmaceuticals with the latest imaging systems and workflow software systems to provide end-to-end diagnostic solutions. It is a major player in the market for radiopharmaceuticals and radioisotopes, with its solid presence in Asia Pacific. This can be attributed to nuclear medicine developments through partnerships with hospitals and regional supply facilities, as well as the continued investment in developing precision diagnostics and positioning.

Cardinal Health (US)

Cardinal Health is a significant participant in the Asia Pacific nuclear medicine market due to its radiopharmacy services and distribution capabilities, offering radioisotopes. The company’s products are used in diagnostics and therapy. It offers unit dose radiopharmaceuticals, isotope management, and solutions in logistics that help hospitals and imaging centers deliver nuclear medicine procedures effectively. It has expertise in the handling, regulatory compliance, and supply of radiopharmaceuticals in Asia Pacific. It is a reliable source of short half-life radioisotopes, which makes it a key service-oriented participant in the nuclear medicine ecosystem in the region.  

Market Ranking

The experiences of the radiopharmaceutical and healthcare companies influence the Asia Pacific nuclear medicine market. They modify their strategies to the highly-growth, and supply-sensitive environment of the region. GE HealthCare aids the market by collaborating with radiopharmaceuticals and imaging platforms with imaging workflow solutions to offer hospitals the ability to scale PET and SPECT services without losing tracer availability due to regional collaboration. The key strengths of Cardinal Health include operations of radiopharmacy, expertise in logistics, and procedural support that assists providers in the efficient use of radioisotopes with short half-lives. Curium is becoming more applicable in its ability to produce radioisotopes and develop PET radiopharmaceuticals to serve diagnosing, imaging, and emerging theranostic requirements. On the regional level, Sun Pharmaceutical Industries, Inc. is increasing the manufacturing of radiopharmaceuticals, contributing to its supply on local levels, and enhancing access in the emerging markets of Asia Pacific. These companies are collectively strengthening the performance of isotopes, reliability of the operations, and clinical usage of nuclear medicine throughout the region.

Related Reports:

"Asia Pacific Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18, Rb-82], Alpha Emitters, Beta Emitters [Y-90], Brachytherapy), Application (Onco, Thyroid, Cardio), Procedure, End User (Imaging Center, Hospital) - Forecast to 2030" 

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com